V Serretta

Summary

Country: Italy

Publications

  1. ncbi request reprint Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    Urology 60:623-7. 2002
  2. ncbi request reprint Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 patients
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, and Department of Urology, Civic Hospital, Catanzaro, Italy
    Urol Int 71:16-21. 2003
  3. doi request reprint [Epidemiology of disease conditions in Italy. Has anything changed? Environment, professional exposure, and lifestyle. Is time for screening?]
    Vincenzo Serretta
    Sezione di Urologia, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo Italy
    Urologia 80:3-6. 2013
  4. doi request reprint Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma
    Vincenzo Serretta
    Section of Urology, Maternal Infant, Andrology and Urology Department, University of Palermo, Italy
    Urology 81:277-81. 2013
  5. ncbi request reprint Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions
    Vincenzo Serretta
    Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Palermo, Italy
    Urology 65:65-9. 2005
  6. doi request reprint A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    BJU Int 106:212-7. 2010
  7. doi request reprint Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital
    Vincenzo Serretta
    Department of Urology, University of Palermo, Palermo, Italy
    Urol Int 83:452-7. 2009
  8. doi request reprint Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment
    Vincenzo Serretta
    Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases Section of Urology, University of Palermo, Palermo, Italy
    J Urol 180:886-90; discussion 891. 2008
  9. doi request reprint Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    Urol Int 82:318-23. 2009
  10. ncbi request reprint PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients
    V Serretta
    Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, Institute of Urology, University of Palermo, Palermo, Italy
    Prostate Cancer Prostatic Dis 11:148-52. 2008

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    Urology 60:623-7. 2002
    ..Any comparison with transurethral resection of the prostate can be invalidated by complications of open surgery because of the lack of an adequate healthcare system and technology...
  2. ncbi request reprint Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 patients
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, and Department of Urology, Civic Hospital, Catanzaro, Italy
    Urol Int 71:16-21. 2003
    ..The Sicilian-Calabrian Society of Urology performed a retrospective survey to assess the management of BPH in southern Italy in 1997 and 1998...
  3. doi request reprint [Epidemiology of disease conditions in Italy. Has anything changed? Environment, professional exposure, and lifestyle. Is time for screening?]
    Vincenzo Serretta
    Sezione di Urologia, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo Italy
    Urologia 80:3-6. 2013
    ..Chlorination or water pollution by pesticides and other chemical factors is considered a relevant risk factor. Familiarity and genetic predisposition, diet and individual risk factors should be taken into account...
  4. doi request reprint Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma
    Vincenzo Serretta
    Section of Urology, Maternal Infant, Andrology and Urology Department, University of Palermo, Italy
    Urology 81:277-81. 2013
    ..To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non-muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy...
  5. ncbi request reprint Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions
    Vincenzo Serretta
    Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Palermo, Italy
    Urology 65:65-9. 2005
    ..To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations...
  6. doi request reprint A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    BJU Int 106:212-7. 2010
    ..To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated...
  7. doi request reprint Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital
    Vincenzo Serretta
    Department of Urology, University of Palermo, Palermo, Italy
    Urol Int 83:452-7. 2009
    ..Well-tolerated outpatient chemotherapy regimens for patients unfit and/or unwilling to be admitted to hospital are needed...
  8. doi request reprint Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment
    Vincenzo Serretta
    Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases Section of Urology, University of Palermo, Palermo, Italy
    J Urol 180:886-90; discussion 891. 2008
    ..In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma...
  9. doi request reprint Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma
    Vincenzo Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    Urol Int 82:318-23. 2009
    ..Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder...
  10. ncbi request reprint PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients
    V Serretta
    Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, Institute of Urology, University of Palermo, Palermo, Italy
    Prostate Cancer Prostatic Dis 11:148-52. 2008
    ..03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml...
  11. ncbi request reprint Optimizing intravesical chemotherapy in patient with non muscle invasive bladder carcinoma
    Vincenzo Serretta
    Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Italy
    Arch Ital Urol Androl 80:143-8. 2008
    ....
  12. ncbi request reprint [Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study]
    Vincenzo Serretta
    Sezione di Urologia, Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefro Urologiche Università degli Studi di Palermo, Italy
    Urologia 77:240-7. 2010
    ..A prospective pilot trial was designed to evaluate the adoption of a single dose of prulifloxacin to prevent the toxicity of BCG. Treatment tolerability and its possible influence on BCG efficacy have been analyzed...
  13. ncbi request reprint TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years
    Vincenzo Serretta
    Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Via Malaspina 136, 90145 Palermo, Italy
    Eur Urol 45:730-5; discussion 735-6. 2004
    ..To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy...
  14. ncbi request reprint Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study
    V Serretta
    Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Italy
    BJU Int 92:545-49; discussion 549-50. 2003
    ..To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy...
  15. ncbi request reprint Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma
    Vincenzo Serretta
    Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro Urological Diseases, University of Palermo, Via Malaspina 136, 90145, Palermo, Italy
    J Cancer Res Clin Oncol 129:472-6. 2003
    ..To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences...
  16. ncbi request reprint Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation
    V Serretta
    Department of Urology at University of Palermo, Palermo, Italy
    Urol Int 77:152-8. 2006
    ..The distribution of potential environmental risk factors among patients affected by superficial transitional cell carcinoma of the bladder (TCCB) has been analyzed...
  17. ncbi request reprint PSA and second-line therapy of hormone refractory prostate carcinoma
    V Serretta
    Institute of Urology, University of Palermo, Palermo, Italy
    Urol Int 66:131-4. 2001
    ..In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient...
  18. ncbi request reprint Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder
    V Serretta
    Department of Urology, Civic Hospital Benfratelli, Palermo, Italy
    Eur Urol 38:419-25. 2000
    ..To evaluate NMP22, BTA-Stat and BTA-Trak tests in monitoring recurrent transitional cell carcinoma of the bladder...
  19. ncbi request reprint Correlation between chronic prostatitis syndrome and pelvic venous disease: a survey of 2,554 urologic outpatients
    C Pavone
    Institute of Urology, University of Palermo, Italy
    Eur Urol 37:400-3. 2000
    ..In this study we evaluated the association between chronic prostatitis syndrome (CPS), varicocele and hemorrhoids as manifestations of a pelvic venous disease...
  20. ncbi request reprint A randomized phase II study of estramustine phosphate versus estramustine phosphate plus etoposide in hormone refractory prostate cancer (HRPC)
    F Fulfaro
    University of Palermo, Palermo, Italy University of Sassari, Sassari, Italy University of Naples, Naples, Italy Civic Hospital, Caltagirone, Italy University of Catania, Catania, Italy Civic Hospital, Trapani, Italy Civic Hospital, Siracusa, Italy
    J Clin Oncol 26:20632. 2008
    ..The aim of this phase II randomized study is to investigate the efficacy and safety of low-dose chemotherapy regimen adopting a combination of EMP and VP16 in patients affected by HRPC...
  21. ncbi request reprint Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction
    C Pavone
    Department of Urology, University of Palermo, Palermo, Italy
    J Urol 172:2347-9. 2004
    ..We established the efficacy and safety of sublingual apomorphine compared with oral sildenafil in comparable groups of patients with erectile dysfunction (ED)...
  22. ncbi request reprint Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin
    M Pavone Macaluso
    Interdepartment Center for Research in Clinical Oncology, University of Palermo, Italy
    J Chemother 5:207-11. 1993
    ..The sequential intravesical combination of epirubicin and interferon-alpha-2b has shown, in our personal experience, encouraging clinical results and our laboratory data suggest the synergic activation of the local immune response...
  23. ncbi request reprint Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients
    V Serretta
    Department of Urology, Civic Hospital, Palermo, Italy
    Urology 52:793-6. 1998
    ..To evaluate the nuclear matrix protein 22 (NMP22) test in the management of patients after transurethral resection (TUR) of recurrent transitional cell carcinoma of the bladder...
  24. ncbi request reprint Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:919-26; discussion 926. 2006
    ..We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort...
  25. ncbi request reprint Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 173:1518-25. 2005
    ..We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort...
  26. doi request reprint Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
    Georg C Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 101:561-5. 2008
    ..To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC)...